Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Noh, E. J.
Right arrow Articles by Lee, J.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Noh, E. J.
Right arrow Articles by Lee, J.-S.
[Cancer Research 65, 11400-11410, December 15, 2005]
© 2005 American Association for Cancer Research


Cell and Tumor Biology

Methyl CpG–Binding Domain Protein 3 Mediates Cancer-Selective Cytotoxicity by Histone Deacetylase Inhibitors via Differential Transcriptional Reprogramming in Lung Cancer Cells

Eun Joo Noh1,2, Eun Ryoung Jang1,2, Gajin Jeong2, You Mie Lee3, Churl Ki Min4 and Jong-Soo Lee1,4

1 Research Institute, National Cancer Center, Goyang, Korea; 2 College of Natural Sciences, Seoul National University, Seoul, Korea; 3 Kyungbook National University, Daegu, Korea; and 4 College of Natural Sciences, Ajou University, Suwon, Korea

Requests for reprints: Jong-Soo Lee, College of Natural Sciences, Ajou University, San 5 Wonchun-Dong Yeongtong-Gu Suwon, 443-749, Korea. Phone: 82-31-219-1886; Fax: 82-31-219-1615; E-mail: jsjlee{at}mail.ajou.ac.kr.

Histone deacetylase inhibitors (HDI) have been reported to inhibit the growth and survival of cancer cells while leaving normal cells untouched. However, the mechanisms underlying this selective cell death are poorly understood. Gene expression analysis revealed that HDI treatment induced up-regulation of p21WAF1/Cip1 and down-regulation of ErbB2 in cancer cells but not normal cells. Overexpression of p21WAF1/Cip1 and/or silencing of ErbB2 enhanced cancer cell growth inhibition, suggesting that HDI-induced up-regulation/down-regulation of these genes play critical roles in HDI-induced growth inhibition of cancer cells. Most importantly, we found that the gene silencing factor methyl CpG–binding domain protein 3 (MBD3) was not only released from cancer-selective promoter of the HDI up-regulated p21WAF1/Cip1 gene but also recruited to that of the HDI-down-regulated ErbB2 gene. Furthermore, silencing of MBD3 by small interfering RNA abrogated the HDI-induced gene regulation and growth inhibition in lung cancer but not in normal cells. Together, our results support the critical potential of MBD3 in HDI-induced cancer-selective cell death via cancer differential gene expression. (Cancer Res 2005; 65(24): 11400-10)




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. Russo, G. A. Balogh, I. H. Russo, and and the Fox Chase Cancer Center Hospital Network P
Full-term Pregnancy Induces a Specific Genomic Signature in the Human Breast
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 51 - 66.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.